U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C3F8
Molecular Weight 188.0193
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERFLUTREN

SMILES

FC(F)(F)C(F)(F)C(F)(F)F

InChI

InChIKey=QYSGYZVSCZSLHT-UHFFFAOYSA-N
InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11

HIDE SMILES / InChI
Molecular Formula C3F8
Molecular Weight 188.0193
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Perflutren is a diagnostic drug that is used for the contrast enhancement during echocardiographic. It consists of lipid-coated microspheres filled with octafluoropropane gas. Ultrasound waves make the microspheres resonate and reflect a strong signal to an ultrasound machine. This results in a difference of density between gas-filled bubbles and blood around them and improves contrast of resulting images. Perflutren is used in patients with suboptimal echocardiograms to opacify the left ventricular chamber and improve the delineation of the heart borders.

Approval Year

1997
172
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Approved
8429
DEFINITY

Approved Use

DEFINITY is an ultrasound contrast agent indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

Launch Date

9.965376E11
Doses

Doses

DosePopulationAdverse events​
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
Disc. AE: Urticaria, Pruritus...
AEs leading to
discontinuation/dose reduction:
Urticaria
Pruritus
Dizziness
Chest pain
Dyspnea
Back pain
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1
Disc. AE: Anaphylactoid reaction...
AEs leading to
discontinuation/dose reduction:
Anaphylactoid reaction (serious)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Disc. AE: Cardiac arrest, Respiratory arrest...
AEs leading to
discontinuation/dose reduction:
Cardiac arrest (grade 5)
Respiratory arrest (grade 5)
Shock (serious)
Syncope (serious)
Arrhythmia (serious)
Hypertension (serious)
Hypotension (serious)
Dyspnea (serious)
Hypoxia (serious)
Chest pain (serious)
Respiratory distress (serious)
Stridor (serious)
Wheezing (serious)
Loss of consciousness (serious)
Convulsions (serious)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
AEs

AEs

AESignificanceDosePopulation
Back pain Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
Chest pain Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
Dizziness Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
Dyspnea Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
Pruritus Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
Urticaria Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.6
Anaphylactoid reaction serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1
Cardiac arrest grade 5
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Respiratory arrest grade 5
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Arrhythmia serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Chest pain serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Convulsions serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Dyspnea serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Hypertension serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Hypotension serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Hypoxia serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Loss of consciousness serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Respiratory distress serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Shock serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Stridor serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Syncope serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Wheezing serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf
Page: p.1, 5
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY456877
https://www.001chemical.com/chem/76-19-7
3B Scientific (Wuhan) Corp
3B3-051504
http://www.3bsc.com/index/pro_info.php?id=89205
AHH Chemical co.,ltd
MT-20856
http://www.ahhchemical.com/product/MT-20856.html
Aceschem
ACF024078
https://www.aceschem.com/catalog/76-19-7.html
Ambinter
Amb10840757
http://www.ambinter.com/reference/10840757
Angene
AGN-PC-0JK7KY
http://www.angenechemical.com/productshow/AGN-PC-0JK7KY.html
Avantor Inc
101178-534
https://us.vwr.com/store/catalog/product.jsp?catalog_number=101178-534
Avantor Inc
200004-456
https://us.vwr.com/store/product/18604304/bovine-serum-albumin-bsa-lyophilized-powder-acros-organics
Avantor Inc
700011-226
https://us.vwr.com/store/product/7829013/bovine-serum-albumin-bsa-spectrum-chemical
Avantor Inc
700011-228
https://us.vwr.com/store/product/7829013/bovine-serum-albumin-bsa-spectrum-chemical
Avantor Inc
700011-230
https://us.vwr.com/store/product/7829027/bovine-serum-albumin-bsa-spectrum-chemical
BOC Sciences
9048-46-8
https://www.bocsci.com/albumin-from-bovine-serum-cas-9048-46-8-item-382204.html
ChemFish Tokyo co.,ltd
6432
http://www.chemfish.com/
ChemMol
49416688
http://www.chemmol.com/chemmol/49416688.html
ChemMol
49423611
http://www.chemmol.com/chemmol/49423611.html
ChemMol
99147238
http://www.chemmol.com/chemmol/99147238.html
Debye Scientific
DB-056033
http://www.debyesci.com/cas_76-19-7.html
Finetech
FT-0621948
http://www.finetechnology-ind.com/prod/detail/pub/70024-90-7.html
Finetech
FT-0631321
http://www.finetechnology-ind.com/prod/detail/pub/76-19-7.html
Molcore
MC456877
https://www.molcore.com/product/76-19-7
Smolecule
S539039
http://www.smolecule.com/products/s539039
THE BioTek
bt-278563
https://www.thebiotek.com/product/inhibitors/bt-278563
VladaChem
VL260738-1G
https://www.vladachem.com/product.php?products=9048-46-8
VladaChem
VL279346-100G
https://www.vladachem.com/product.php?products=9048-46-8
abcr GmbH
AB104454
http://www.abcr.com/shop/en/AB104454
abcr GmbH
AB128946
http://www.abcr.de/shop/en/AB128946
eNovation Chemicals
D628372
https://www.enovationchem.com/ProductDetails.asp?ProductID=D628372
iChemical
EBD34753
http://www.ichemical.com/products/76-19-7.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
iChemical
EBD3015254
http://www.ichemical.com/products/9048-46-8.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Results of vitrectomy and the no-touch-technique using autologous adjuvants in macular hole treatment.
2001
Bioeffects of myocardial contrast microbubble destruction by echocardiography.
2002 Aug
Phacovitrectomy with internal limiting membrane peeling for idiopathic macular hole.
2002 Aug
Pressure-dependent attenuation in ultrasound contrast agents.
2002 Aug
Effects of Optison on pulmonary gas exchange and hemodynamics.
2002 Aug
Automated endocardial border detection and evaluation of left ventricular function from contrast-enhanced images using modified acoustic quantification.
2002 Aug
Effects of preoperative and postoperative epiretinal membranes on macular hole closure and visual restoration.
2002 Aug
Contrast-assisted destruction-replenishment ultrasound for the assessment of tumor microvasculature in a rat model.
2002 Dec
Management of submacular hemorrhage.
2002 Dec
Understanding the limitations of ultrasonic backscatter measurements from microbubble populations.
2002 Dec 7
The dependence of ultrasound contrast agents backscatter on acoustic pressure: theory versus experiment.
2002 May
Intravitreal gas injection for the treatment of experimental vitreous hemorrhage in rabbits.
2002 Nov
Evaluation of posturing in macular hole surgery.
2002 Nov
Ultrasound increases plasmid-mediated gene transfer to dystrophic muscles without collateral damage.
2002 Nov
Loss of vision caused by expansion of intraocular perfluoropropane (C(3)F(8)) gas during nitrous oxide anesthesia.
2002 Nov
Combined perfluoropropane gas and viscoelastic material injection for anterior chamber reformation following trabeculectomy.
2002 Nov
A biological model of tamponade gases following pneumatic retinopexy.
2002 Oct
Complications of general anesthesia using nitrous oxide in eyes with preexisting gas bubbles.
2002 Oct
Central retinal artery occlusion caused by expansion of intraocular gas at high altitude.
2002 Oct
Angle closure glaucoma following pupillary block in an aphakic perfluoropropane gas-filled eye.
2002 Sep
Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome.
2002 Sep
Nitrous oxide anaesthesia in the presence of intraocular gas can cause irreversible blindness.
2002 Sep 7
Lower receiving frequencies than transmitting frequencies could yield improved results for contrast imaging: an in vivo study in closed chest canines.
2003 Apr
Anatomic and functional results of vitrectomy and long-term intraocular tamponade for stage 2 macular holes.
2003 Feb
Indocyanine green assisted retinal internal limiting membrane removal in stage 3 or 4 macular hole surgery.
2003 Jan
Management of retinal detachment in osteogenesis imperfecta.
2003 Jul
Influence of contrast ultrasonography with perflutren lipid microspheres on microvessel injury.
2003 Jul
Vitrectomy with internal limiting membrane peeling for macular retinoschisis and retinal detachment without macular hole in highly myopic eyes.
2003 Jul
Repair of late Descemet's membrane detachment with perfluoropropane gas.
2003 Jun
Comparison of silicone oil versus gas tamponade in the treatment of idiopathic full-thickness macular hole.
2003 Jun
Topical medication interferes with face-down positioning after macular hole surgery.
2003 Jun
Contrast echocardiography using intravenous octafluoropropane and real-time perfusion imaging predicts functional recovery after acute myocardial infarction.
2003 Jun
Microbubble-augmented ultrasound declotting of thrombosed arteriovenous dialysis grafts in dogs.
2003 Mar
Inverted pneumatic retinopexy: a method of treating retinal detachments associated with inferior retinal breaks.
2003 Mar
The behaviour of individual contrast agent microbubbles.
2003 May
Macular hole secondary to fungal endophthalmitis.
2003 May
Long-term anatomic and visual acuity outcomes after initial anatomic success with macular hole surgery.
2003 May
Intestinal and hepatic lesions in mice, rats, and other laboratory animals after intravenous administration of gas-carrier contrast agents used in ultrasound imaging.
2003 May 1
Inverted pneumatic retinopexy.
2003 Nov
Inverted pneumatic retinopexy.
2003 Nov
Vitrectomy with indocyanine green-guided inner limiting membrane peeling for a Q-switched Nd:YAG laser-induced macular hole.
2003 Oct
Perfluorocarbon liquid utilization in primary vitrectomy repair of retinal detachment with multiple breaks.
2003 Oct
Early macular holes with retinoschisis in highly myopic eyes.
2003 Oct
Comparison of scleral buckling with combined scleral buckling and pars plana vitrectomy in the management of rhegmatogenous retinal detachment with unseen retinal breaks.
2003 Oct
Better success of retinal reattachment with long-standing gas tamponade in highly myopic eyes.
2003 Oct
Ultrasound-mediated cavitation thresholds of liquid perfluorocarbon droplets in vitro.
2003 Sep
Extra-low acoustic power harmonic images of the liver with perflutren: novel imaging for real-time observation of liver perfusion.
2003 Sep
A pilot study of pars plana vitrectomy, intraocular gas, and radial neurotomy in ischaemic central retinal vein occlusion.
2003 Sep
Comparison of intravenous myocardial contrast echocardiography and low-dose dobutamine echocardiography for predicting left ventricular functional recovery following acute myocardial infarction.
2003 Sep 1
Real-time assessment of myocardial perfusion during balloon angioplasty of the left anterior descending coronary artery.
2003 Sep 15
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:35:37 UTC 2023
Edited
by admin
on Fri Dec 15 16:35:37 UTC 2023
Record UNII
CK0N3WH0SR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PERFLUTREN
EMA EPAR   II   INN   JAN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
LUMINITY
Brand Name English
DMP115
Code English
OCTAFLUORO-PROPANE
Systematic Name English
PERFLUTREN [EMA EPAR]
Common Name English
PERFLUOROPROPANE
MI  
Systematic Name English
PERFLUTREN [VANDF]
Common Name English
Octafluoropropane
VANDF  
Systematic Name English
OCTAFLUOROPROPANE [VANDF]
Common Name English
PERFLUOROPROPANE [MI]
Common Name English
1,1,1,2,2,3,3,3-OCTAFLUOROPROPANE
Systematic Name English
OPTISON
Brand Name English
FS069
Code English
OXTAFLUOROPROPANE [VANDF]
Common Name English
PERFLUTREN [ORANGE BOOK]
Common Name English
PROPANE, OCTAFLUORO-
Systematic Name English
DMP-115
Code English
perflutren [INN]
Common Name English
Perflutren [WHO-DD]
Common Name English
PERFLUTREN [USAN]
Common Name English
FS-069
Code English
PERFLUTREN [MART.]
Common Name English
MRX-115
Code English
DEFINITY
Brand Name English
PERFLUTREN [II]
Common Name English
PERFLUOROPROPANE [INCI]
Common Name English
PERFLUTREN [JAN]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS LUMINITY (AUTHORIZED: ECHOCARDIOGRAPHY)
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
NDF-RT N0000175864
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
EMA ASSESSMENT REPORTS OPTISON (AUTHORIZED: ECHOCARDIOGRAPHY)
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
NCI_THESAURUS C1937
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
NDF-RT N0000010259
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C47664
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
LACTMED
Perflutren
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
SMS_ID
100000090070
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
CHEBI
31980
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
MESH
C418027
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
INN
7932
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
HSDB
8074
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
WIKIPEDIA
OCTAFLUOROPROPANE
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
RXCUI
283753
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY RxNorm
DAILYMED
CK0N3WH0SR
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
ChEMBL
CHEMBL1663
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
FDA UNII
CK0N3WH0SR
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
PUBCHEM
6432
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
MESH
C042852
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
DRUG CENTRAL
2104
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
CAS
76-19-7
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-941-9
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
DRUG BANK
DB00556
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
EVMPD
SUB20657
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
MERCK INDEX
m8543
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID9052503
Created by admin on Fri Dec 15 16:35:38 UTC 2023 , Edited by admin on Fri Dec 15 16:35:38 UTC 2023
PRIMARY
Related Record Type Details
Structure of PERFLUTREN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966